Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT05203380 · COMPLETED

Trial details

NCT number: NCT05203380
Sponsor: Regeneron Pharmaceuticals
Status: COMPLETED
Study type: OBSERVATIONAL

Moderate-to-severe Atopic Dermatitis

Start date: 2022-01-27
Primary completion: 2023-03-10
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.